Neuroepo multisession
收藏资源简介：
The quest for neuroprotection in Parkinson’s disease (PD) has been for new compounds to slow disease progression and stable and non-invasive biomarkers to document their benefits. Neuroepo, a new formulation of EPO with low content of sialic acid reported good results in animal model and tolerance in healthy participants and PD patients. In a double-blind randomized placebo (https://clinicaltrials.gov/ number NCT04110678) twenty-five PD patients were assigned randomly to Neuroepo (n=15) or placebo (n=10) groups we reported the tolerance of the drug. We recorded resting-state EEG before and six months after the administration of the drug. The qualitative analysis of the abnormalities of the EEG was evaluated by two experts using a Likert-type scale and a multivariate item response theory (MIRT) approach was employed to establish the differences between groups in the two times. The quantitative EEG (qEEG) analysis was performed at the sources looking for generators of the neural activity using software VARETA and co-registering the results using the Montreal Neurological Institute Atlas. The statistical analysis between the sources was conducted using a permutation test and later a contrast method using the surfstat software between groups and before vs after condition, with Bonferroni correction for multiple comparisons. Here in this repository, we placed the raw EEG in BIDS format (Pernet, C. R. et al. EEG-BIDS, an extension to the brain imaging data structure for electroencephalography. Sci. data 6, 103 (2019). For the use of VARETA the qEEG program you can use (Bosch-Bayard, J. et al. A Quantitative EEG Toolbox for the MNI Neuroinformatics Ecosystem: Normative SPM of EEG Source Spectra. Front. Neuroinform. 14, (2020).) The EEG dataset from the different stages of processing can be requested to the authors.
针对帕金森病（Parkinson’s Disease, PD）的神经保护研究，始终致力于开发可延缓疾病进程的新型化合物，以及能够验证其疗效的稳定无创生物标志物。Neuroepo是促红细胞生成素（Erythropoietin, EPO）的新型制剂，其唾液酸（sialic acid）含量较低，既往在动物模型中展现出良好效果，且在健康受试者与帕金森病患者中均表现出良好耐受性。 在这项双盲随机安慰剂对照临床试验（临床试验注册号：NCT04110678，可通过https://clinicaltrials.gov/查询）中，25名帕金森病患者被随机分配至Neuroepo组（n=15）与安慰剂组（n=10），本研究报告了该药物的耐受性数据。研究人员在给药前及给药6个月后，分别记录了受试者的静息态脑电图（resting-state electroencephalography, EEG）。 针对脑电图异常的定性分析由两名专家采用李克特（Likert）量表完成；同时采用多变量项目反应理论（Multivariate Item Response Theory, MIRT）方法，以比较两次测量时点下两组间的差异。定量脑电图（quantitative electroencephalography, qEEG）分析采用VARETA软件，以定位神经活动的产生源为目标开展，并借助蒙特利尔神经学研究所图谱（Montreal Neurological Institute Atlas）对分析结果进行配准。 针对脑电源点的统计分析首先采用置换检验，随后借助surfstat软件完成组间及给药前后的差异对比，并通过邦费罗尼（Bonferroni）校正以控制多重比较的假阳性率。 本数据集仓库中存储了采用BIDS格式整理的原始脑电图数据（引用文献：Pernet, C. R. 等人. EEG-BIDS：面向脑电图的脑成像数据结构扩展. 《Scientific Data》6, 103 (2019)）。若需使用适配VARETA的定量脑电图工具包，可参考以下文献：Bosch-Bayard, J. 等人. 面向MNI神经信息学生态系统的定量脑电图工具箱：脑电源频谱的标准化SPM. 《Frontiers in Neuroinformatics》14, (2020)。 不同处理阶段的脑电图数据集可向本文作者申请获取。
